Jean Yves Douillard

Summary

Affiliation: Institut Paoli-Calmettes
Country: France

Publications

  1. ncbi Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial
    Jean Yves Douillard
    Centre Rene Gauducheau, Nantes, France
    Lancet Oncol 7:719-27. 2006
  2. ncbi Update on European adjuvant trials with irinotecan for colorectal cancer
    Jean Yves Douillard
    Centre Rene Gauducheau, CRLCC Nantes Atlantique, St Herblain Nantes, France
    Oncology (Williston Park) 16:13-5. 2002
  3. pmc Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib
    Charles S Harmon
    Pfizer Oncology, La Jolla, CA, USA
    J Transl Med 9:120. 2011
  4. ncbi Comparison of docetaxel- and vinca alkaloid-based chemotherapy in the first-line treatment of advanced non-small cell lung cancer: a meta-analysis of seven randomized clinical trials
    Jean Yves Douillard
    Centre R Gauducheau, St Herblain, France
    J Thorac Oncol 2:939-46. 2007
  5. doi Is XELOX equivalent to FOLFOX or other continuous-infusion 5-fluorouracil chemotherapy in metastatic colorectal cancer?
    Jean Yves Douillard
    Department of Medical Oncology, Centre R Gauducheau, St Herblain, France
    Clin Colorectal Cancer 7:206-11. 2008
  6. doi Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the Lung Adjuvant Cisplatin Evaluation
    Jean Yves Douillard
    Department of Medical Oncology, Centre R Gauducheau, St Herblain, France
    J Thorac Oncol 5:220-8. 2010
  7. doi Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study
    Jean Yves Douillard
    Centre Rene Gauducheau, Nantes, France
    J Clin Oncol 28:4697-705. 2010
  8. ncbi ZD0473 combined with other chemotherapeutic agents for the treatment of solid malignancies
    J Y Douillard
    CRLCC Nantes Atlantique, Nantes Saint Herblain, France
    Eur J Cancer 38:S25-31. 2002
  9. ncbi Irinotecan-based regimens in the adjuvant therapy of colorectal cancer
    Jean Yves Douillard
    Department of Medical Oncology, Centre R Gauducheau, Nantes St Herblain, France
    Clin Colorectal Cancer 5:S34-7. 2005
  10. ncbi Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer
    Jean Yves Douillard
    Centre Rene Gauducheau, Nantes, France
    J Clin Oncol 20:3605-16. 2002

Detail Information

Publications41

  1. ncbi Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial
    Jean Yves Douillard
    Centre Rene Gauducheau, Nantes, France
    Lancet Oncol 7:719-27. 2006
    ..We aimed to compare the effect of adjuvant vinorelbine plus cisplatin versus observation on survival in patients with completely resected NSCLC...
  2. ncbi Update on European adjuvant trials with irinotecan for colorectal cancer
    Jean Yves Douillard
    Centre Rene Gauducheau, CRLCC Nantes Atlantique, St Herblain Nantes, France
    Oncology (Williston Park) 16:13-5. 2002
    ..This article will review the inclusion criteria and goal of these European trials. An update on accrual and on tolerance will also be provided...
  3. pmc Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib
    Charles S Harmon
    Pfizer Oncology, La Jolla, CA, USA
    J Transl Med 9:120. 2011
    ..In a phase II study of sunitinib in advanced HCC, we evaluated the plasma pharmacodynamics of five proteins related to the mechanism of action of sunitinib and explored potential correlations with clinical outcome...
  4. ncbi Comparison of docetaxel- and vinca alkaloid-based chemotherapy in the first-line treatment of advanced non-small cell lung cancer: a meta-analysis of seven randomized clinical trials
    Jean Yves Douillard
    Centre R Gauducheau, St Herblain, France
    J Thorac Oncol 2:939-46. 2007
    ..To compare the impact on overall survival (OS) of docetaxel-based chemotherapy versus vinca alkaloid-based regimens for first-line therapy of advanced non-small cell lung cancer...
  5. doi Is XELOX equivalent to FOLFOX or other continuous-infusion 5-fluorouracil chemotherapy in metastatic colorectal cancer?
    Jean Yves Douillard
    Department of Medical Oncology, Centre R Gauducheau, St Herblain, France
    Clin Colorectal Cancer 7:206-11. 2008
    ..Patient preference, quality of life, and cost of treatment could also be considered in this setting, wherein most of the patients are not in a curative situation...
  6. doi Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the Lung Adjuvant Cisplatin Evaluation
    Jean Yves Douillard
    Department of Medical Oncology, Centre R Gauducheau, St Herblain, France
    J Thorac Oncol 5:220-8. 2010
    ..Patients randomized to cisplatin-vinorelbine or observation were the largest subgroup (41%) and the most homogeneous in terms of drug doses and eligibility...
  7. doi Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study
    Jean Yves Douillard
    Centre Rene Gauducheau, Nantes, France
    J Clin Oncol 28:4697-705. 2010
    ....
  8. ncbi ZD0473 combined with other chemotherapeutic agents for the treatment of solid malignancies
    J Y Douillard
    CRLCC Nantes Atlantique, Nantes Saint Herblain, France
    Eur J Cancer 38:S25-31. 2002
    ..6%), neutropenia (36.4%) and anaemia (18.2%). No objective responses were observed in either trial, but disease stabilisation occurred in 29.2% and 27.3% of patients in the vinorelbine and topotecan trials, respectively...
  9. ncbi Irinotecan-based regimens in the adjuvant therapy of colorectal cancer
    Jean Yves Douillard
    Department of Medical Oncology, Centre R Gauducheau, Nantes St Herblain, France
    Clin Colorectal Cancer 5:S34-7. 2005
    ..These results should provide important new insights as to how to manage stage II/III colon cancer...
  10. ncbi Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer
    Jean Yves Douillard
    Centre Rene Gauducheau, Nantes, France
    J Clin Oncol 20:3605-16. 2002
    ..Safety was also compared...
  11. ncbi Sequential two-line strategy for stage IV non-small-cell lung cancer: docetaxel-cisplatin versus vinorelbine-cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: final results of a randomised phase II study
    J Y Douillard
    Centre Rene Gauducheau, Saint Herblain, France
    Ann Oncol 16:81-9. 2005
    ..This phase II trial compared docetaxel-cisplatin (DC) with vinorelbine-cisplatin (VC), both as first-line therapy followed by cross-over at progression to single-agent vinorelbine or docetaxel in advanced non-small-cell lung cancer (NSCLC)...
  12. doi Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer
    Jean Yves Douillard
    Institut de Cancérologie de l Ouest ICO René Gauducheau, Nantes, France
    N Engl J Med 369:1023-34. 2013
    ..Other activating RAS mutations may also be negative predictive biomarkers for anti-EGFR therapy...
  13. doi Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study
    Jaafar Bennouna
    Centre Rene Gauducheau, Nantes, France
    Clin Colorectal Cancer 11:38-44. 2012
    ..This prospective phase II study assessed the efficacy and safety of bevacizumab plus chemotherapy regimens commonly used in the second-line treatment of metastatic colorectal cancer (mCRC)...
  14. doi Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized
    Jean Yves Douillard
    Centre R Gauducheau, Nantes, France
    Int J Radiat Oncol Biol Phys 72:695-701. 2008
    ..To study the impact of postoperative radiation therapy (PORT) on survival in the Adjuvant Navelbine International Trialist Association (ANITA) randomized study of adjuvant chemotherapy...
  15. doi Impact of histology on survival of resected non-small cell lung cancer (NSCLC) receiving adjuvant chemotherapy: subgroup analysis of the adjuvant vinorelbine (NVB) cisplatin (CDDP) versus observation in the ANITA trial
    Jaafar Bennouna
    Centre Rene Gauducheau, Bd J Monod, 44805 Nantes, France
    Lung Cancer 74:30-4. 2011
    ..Data issued from the survival outcome in the ANITA trial are reported according to histology in observation (n=433) and adjuvant chemotherapy arms (n=407)...
  16. doi A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens
    Jaafar Bennouna
    Medical Oncology Branch, Centre Rene Gauducheau, Bd J Monod, 44805 Saint Herblain, France
    Invest New Drugs 29:1021-8. 2011
    ..To assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) in patients with metastatic colorectal cancer who had failed one or two previous chemotherapeutic regimens that included oxaliplatin and/or irinotecan...
  17. ncbi Randomized phase II feasibility study of combining the matrix metalloproteinase inhibitor BMS-275291 with paclitaxel plus carboplatin in advanced non-small cell lung cancer
    Jean Yves Douillard
    Centre Rene Gauducheau, Nantes, France
    Lung Cancer 46:361-8. 2004
    ....
  18. ncbi Therapeutic strategies for colorectal cancer in Europe and the United States: focus on chemotherapy for advanced colorectal cancer
    Jaafar Bennouna
    Centre Rene Gauducheau, Boulevard J Monod 44 805, Nantes Saint Herblain, France
    Int J Clin Oncol 7:236-44. 2002
  19. ncbi Prospects for colorectal cancer treatment: oral chemotherapy and targeted biotherapy
    Jaafar Bennouna
    Centre Rene Gauducheau, Nantes Saint Herblain, France
    Expert Rev Anticancer Ther 3:505-17. 2003
    ..This review will focus upon new anticancer drugs, some of them with original mechanism of action, and steps towards the goal of better understanding and anticipating new treatments in colorectal carcinoma...
  20. doi Human T(H)17 immune cells specific for the tumor antigen MAGE-A3 convert to IFN-γ-secreting cells as they differentiate into effector T cells in vivo
    Ahmed Hamai
    Institut National de la Sante et de la Recherche Medicale, Unité 1102, institut de cancérologie de l Ouest, Saint Herblain, France
    Cancer Res 72:1059-63. 2012
    ....
  21. doi The role of UFT in metastatic colorectal cancer
    Jaafar Bennouna
    Centre R Gauducheau, St Herblain, France
    Oncology 76:301-10. 2009
    ..UFT can be considered a rational replacement for intravenous 5-FU in the first- and second-line treatment of patients with mCRC...
  22. ncbi [Interleukin-2 and interferon in metastatic kidney cancer. Experience of the French Immunotherapy Group]
    Sylvie Negrier
    Departement d Oncologie Medicale, Centre Leon Berard, 28, rue Laennec, 69373 Lyon
    Prog Urol 12:213-8. 2002
    ..c. cytokine regimens are therefore fairly disappointing. These results were taken into account in the ongoing evaluation programme (Percy programme) based on patient selection as a function of prognostic factors...
  23. ncbi Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie
    Sylvie Negrier
    Department of Biostatistics, Centre Leon Berard, 28 rue Laennec, 69373 Lyon Cedex 08 France
    World J Urol 23:161-5. 2005
    ..Patients who combine at least three of these factors have over 80% probability of rapid progression despite treatment. We think that these results must be taken into account for cytokine treatment decision...
  24. ncbi Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6--from the Groupe Francais d'Immunotherapie
    Sylvie Negrier
    Cytokines and Cancer Research Unit, INSERM U 590 and Medical Oncology Department, Cedex 08, France
    J Clin Oncol 22:2371-8. 2004
    ..Our objective was to analyze the prognostic value of circulating vascular endothelial growth factor (VEGF), interleukin-10 (IL-10), and interleukin-6 (IL-6)...
  25. ncbi Repeat hepatectomy for colorectal liver metastases
    Antoine Hamy
    Clinique Chirurgicale 1, Centre Hospitalier Universitaire Nord, Nantes, France
    Int Surg 90:189-97. 2005
    ..Survival rates for repeat resections of colorectal liver metastases in selected patients were comparable with those obtained after resection of a first liver metastasis...
  26. ncbi Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01)
    Stephane Culine
    Department of Medical Oncology, Centre Regional de Lutte Contre le Cancer, Val d Aurelle, Parc Euromedecine, 34298 Montpellier Cedex 5, France
    J Clin Oncol 21:3479-82. 2003
    ..To evaluate the efficacy and toxicity of novel chemotherapy combinations including cisplatin with gemcitabine (GC) or irinotecan (IC) for patients with carcinomas of an unknown primary site...
  27. ncbi Relationship between EGFR expression, EGFR mutation status, and the efficacy of chemotherapy plus cetuximab in FLEX study patients with advanced non-small-cell lung cancer
    Jean Yves Douillard
    Department of Medical Oncology, institut de cancérologie de l Ouest, Centre Rene Gauducheau, Saint Herblain, France Department of Medicine I, Medical University of Vienna, Vienna, Austria HOPE Directorate, St James s Hospital, Dublin, Ireland Department of Pathology, Aberdeen Royal Infirmary, Aberdeen, United Kingdom Institute of Pathology, University of Witten Herdecke and HELIOS Hospital Wuppertal, Wuppertal, Germany Global Biostatistics, Biomarker Technologies and Operations, and Translational Innovation Platform Oncology, Merck KGaA, Darmstadt, Germany and University Health Network, Department of Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
    J Thorac Oncol 9:717-24. 2014
    ..We assessed whether the treatment effect was also modulated in FLEX study patients by tumor EGFR mutation status...
  28. ncbi [Radiation therapy with 131I-MIBG is still relevant for metastatic carcinoid tumors]
    Aurore Oudoux
    Service de Medecine Nucleaire, Centre Rene Gauducheau, Bd Monod, Saint Herblain
    Gastroenterol Clin Biol 29:935-8. 2005
    ..There are currently no standard treatment options. We present a management strategy for gastrointestinal carcinoid tumors with 131I-MIBG...
  29. ncbi Phase II study of sorafenib in patients with advanced hepatocellular carcinoma
    Ghassan K Abou-Alfa
    Memorial Sloan Kettering Cancer Center, York, NY 10022, USA
    J Clin Oncol 24:4293-300. 2006
    ..This phase II study of sorafenib, an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases, assessed efficacy, toxicity, pharmacokinetics, and biomarkers in advanced hepatocellular carcinoma (HCC) patients...
  30. ncbi Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study
    Cornelis J A Punt
    Department of Medical Oncology, University Medical Center St Radboud, PO Box 9101, 6500 HB Nijmegen, Netherlands
    Lancet 360:671-7. 2002
    ..We did a randomised trial in 27 countries to determine the effect of adding edrecolomab to the combination of fluorouracil and folinic acid in these patients...
  31. ncbi Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer
    Luis Paz-Ares
    Servicio de Oncologia Medica, Doce de Octubre University Hospital, Madrid, Spain
    J Clin Oncol 24:1428-34. 2006
    ....
  32. ncbi Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]
    Masahiro Fukuoka
    Fourth Department of Internal Medicine, Kinki University School of Medicine, 377 2 Ohnohigashi Osakasayama, Osaka 589, Japan
    J Clin Oncol 21:2237-46. 2003
    ....
  33. ncbi Subcutaneous interleukin-2 and interferon alpha in the treatment of patients with metastatic renal cell carcinoma-Less efficacy compared with intravenous interleukin-2 and interferon alpha. Results of a multicenter Phase II trial from the Groupe Français
    Alain Ravaud
    Department of Medicine, Institut Bergonie, Bordeaux, France
    Cancer 95:2324-30. 2002
    ....
  34. ncbi Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18
    Natasha B Leighl
    National Cancer Institute of Canada Clinical Trials Group, Kingston, Canada
    J Clin Oncol 23:2831-9. 2005
    ..In early phase studies, BMS- 275291 was not associated with dose-limiting joint toxicity seen with other MMPIs...
  35. ncbi Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials
    Cornelis J A Punt
    Department of Medical Oncology, Radboud University Nijmegen Medical Center, PO Box 9101 6500 HB Nijmegen, The Netherlands
    J Natl Cancer Inst 99:998-1003. 2007
    ..The proposed guidelines may add to the quality and cross-comparability of future studies of adjuvant treatments for cancer...
  36. doi Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group
    Jean Pierre Pignon
    Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    J Clin Oncol 26:3552-9. 2008
    ..The aim of the Lung Adjuvant Cisplatin Evaluation was to identify treatment options associated with a higher benefit or groups of patients who particularly benefit from postoperative chemotherapy...
  37. doi Potential regional differences for the tolerability profiles of fluoropyrimidines
    Daniel G Haller
    Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA, USA
    J Clin Oncol 26:2118-23. 2008
    ....
  38. ncbi A clinical pharmacokinetic analysis of tegafur-uracil (UFT) plus leucovorin given in a new twice-daily oral administration schedule
    Marie Christine Etienne-Grimaldi
    Oncopharmacology Unit, Centre Antoine Lacassagne, Nice, France
    Clin Pharmacokinet 46:953-63. 2007
    ....
  39. doi Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials
    Gunnar Folprecht
    University Hospital Dresden, Fetscherstr 74, Dresden, Germany 01307
    J Clin Oncol 26:1443-51. 2008
    ..Uncertainty exists about whether elderly patients benefit to the same extent as younger patients from combination therapy with irinotecan in the first-line treatment of metastatic colorectal cancer (CRC)...
  40. ncbi [Standards, Options and Recommendations for the management of non-small cell lung carcinoma patients]
    Alain Depierre
    Bull Cancer 90:151-66. 2003
    ..This is a short version of the SOR guideline covering diagnosis, treatment and follow-up and includes the algorithms for the management of patients with non-small cell lung cancer...
  41. ncbi [2000 Standards, Options and Recommendations for prognostic value of oncogenes and tumor suppressor genes in non small cell lung cancer]
    Jeanne Marie Brechot
    FNCLCC, Standards, Options, Recommandations, 101, rue de Tolbiac, 75654 Paris Cedex 13, France
    Bull Cancer 89:857-67. 2002
    ..The methodology is based on a literature review and critical appraisal by a multidisciplinary group of experts, with feedback from specialists in cancer care delivery...